Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA

References

• Ergin A, Muntner P, Sherwin R et al. Secular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United States. Am. J. Med.117, 219–227 (2004).
   PubMed Web of Science ®Google Scholar
• Stamler J, Vaccaro O, Neaton JD et al. Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened in Multiple Risk Factor Intervention Trial. Diabetes Care16, 434–444 (1993).
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA285, 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation110, 227–239 (2004).
   PubMed Web of Science ®Google Scholar
• Kuulasmaa K, Tunstall-Pedoe H, Dobson A et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet355, 675–687 (2000).
   PubMed Web of Science ®Google Scholar
• Menotti A, Kromhout D, Blackburn H et al. Forty-year mortality from cardiovascular diseases and all causes of death in the US Railroad cohort of the Seven Countries Study. Eur. J. Epidemiol.19, 417–424 (2004).
   PubMed Web of Science ®Google Scholar
• Kotseva K, Wood D, De Backer G et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet373, 929–940 (2009).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Steinberg BA, Murphy SA et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J. Am. Coll. Cardiol.48, 438–445 (2006).
   PubMed Web of Science ®Google Scholar
• Hulten E, Jackson JL, Douglas K et al. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch. Intern. Med.166, 1814–1821 (2006).
   PubMed Web of Science ®Google Scholar
• Olsson AG, Schwartz GG, Szarek M et al. Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study). Am. J. Cardiol.99, 632–635 (2007).
   PubMed Web of Science ®Google Scholar
• Wenger NK, Lewis SJ, Herrington DM et al. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann. Intern. Med.147, 1–9 (2007).
   PubMed Web of Science ®Google Scholar
• Amarenco P, Goldstein LB, Messig M et al. Relative and Cumulative Effects of Lipid and Blood Pressure Control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial. Stroke40(7), 2486–2492 (2009).
   PubMed Web of Science ®Google Scholar
• White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J. Clin. Pharmacol.42, 963–970 (2002).
   PubMed Web of Science ®Google Scholar
• Soran H, Durrington P. Rosuvastatin: efficacy, safety and clinical effectiveness. Expert Opin. Pharmacother.9(12), 2145–2160 (2008).
   PubMed Web of Science ®Google Scholar
• Rader DJ, Davidson MH, Caplan RJ et al. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Am. J. Cardiol.91, C20–C23 (2003).
   PubMed Web of Science ®Google Scholar
• Buckett L, Ballard P, Davidson R et al. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells. Atherosclerosis151, 41 (2000).
   Google Scholar
• Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science11, 1160–1164 (2001).
   Web of Science ®Google Scholar
• McTaggart F, Buckett L, Davidson R et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am. J. Cardiol.87(Suppl. 5A), B28–B32 (2001).
   PubMed Web of Science ®Google Scholar
• Martin PD, Dane AL, Scheneck et al. Disposition of new HMG CoA reductase inhibitor ZD4522 following dosing in healthy subjects. J. Clin. Pharmacol.40, 1056 (2000).
   Google Scholar
• Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br. J. Clin. Pharmacol.54, 472–477 (2002).
   PubMed Web of Science ®Google Scholar
• Martin PD, Dane AL, Nwose OM et al. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J. Clin. Pharmacol.42, 1116–1121 (2002).
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA et al. Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am. J. Cardiol.92, 152–160 (2003).
   PubMed Web of Science ®Google Scholar
• Schuster H, Barter PJ, Stender S et al. Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am. Heart J.147, 705–713 (2004).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bertolami M, Hernandez Garcia HR et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY) II. Am. Heart. J.151, E1–E9 (2006).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J. Am. Coll. Cardiol.52, 626–632 (2008).
   PubMed Web of Science ®Google Scholar
• Leiter LA, Rosenson RS, Stein E et al. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis194, E154–E64 (2007).
   PubMed Web of Science ®Google Scholar
• Fonseca FA, Ruiz A, Cardona-Muñoz EG et al. The DISCOVERY PENTA study: a Direct Statin Comparison of LDL-C Value – an Evaluation of Rosuvastatin Therapy Compared with Atorvastatin. Curr. Med. Res. Opin.21, 1307–1315 (2005).
   PubMed Web of Science ®Google Scholar
• Faergeman O, Hill L, Windler E et al. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology111, 219–228 (2008).
   PubMed Web of Science ®Google Scholar
• Clearfield MB, Amerena J, Bassand JP et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials7, 35 (2006).
   PubMed Web of Science ®Google Scholar
• Stalenhoef AF, Ballantyne CM, Sarti C et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur. Heart J.26, 2664–2672 (2005).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA et al. JUPITER study group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med.359, 2195–2207 (2008).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet373, 1175–1182 (2009).
   PubMed Web of Science ®Google Scholar
• Glynn RJ, Danielson E, Fonseca FA et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N. Engl. J. Med.360, 1851–1861 (2009).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med.342, 836–843 (2000).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Rose L et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med.347, 1557–1565 (2002).
   PubMed Web of Science ®Google Scholar
• Avis HJ, Hutten BA, Gagne C et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia: results from the PLUTO study J. Am. Coll. Cardiol.53(Suppl. 1), A208 (2009).
   Google Scholar
• Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. Pediatrics122, 198–208 (2008).
   PubMed Web of Science ®Google Scholar
• Wiegman A, Hutten BA, de Groot E et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA292, 331–337 (2004).
   PubMed Web of Science ®Google Scholar
• Rodenburg J, Vissers MN, Wiegman A et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation116, 664–668 (2007).
   PubMed Web of Science ®Google Scholar
• Crouse JR 3rd, Raichlen JS, Riley WA et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA297, 1344–1353 (2007).
   PubMed Web of Science ®Google Scholar
• Bots ML, Palmer MK, Dogan S et al. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. J. Intern. Med.265(6), 698–707 (2009).
   PubMed Web of Science ®Google Scholar
• Underhill HR, Yuan C, Zhao XQ et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am. Heart J.155, 584, E1–E8 (2008).
   Web of Science ®Google Scholar
• Miyauchi K, Takaya N, Hirose T et al. Rationale and design of the carotid plaque in human for all evaluations with aggressive rosuvastatin therapy (CHALLENGER trial): evaluation by magnetic resonance imaging. Circ. J.73, 111–115 (2009).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA295, 1556–1565 (2006).
   PubMed Web of Science ®Google Scholar
• Crouse JR III. Thematic review series: patient oriented research; imaging atherosclerosis: state of the art. J. Lipid. Res.47, 1677–1699 (2006).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Granillo GA, Agostoni P, Garcia-Garcia HM et al. Meta-analysis of the studies assessing temporal changes in coronary plaque volume using intravascular ultrasound. Am. J. Cardiol.99, 5–10 (2007).
   PubMed Web of Science ®Google Scholar
• Saam T, Ferguson MS, Yarnykh VL et al. Quantitative evaluation of carotid plaque composition by in vivo MRI. Arterioscler. Thromb. Vasc. Biol.25, 234–239 (2005).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA291, 1071–1080 (2004).
   PubMed Web of Science ®Google Scholar
• AstraZeneca Pharmaceuticals LP. Crestor (Rosuvastatin Calcium) Prescribing Information. AstraZeneca, Wilmington, DE, USA (2003).
   Google Scholar
• Armitage J. The safety of statins in clinical practice. Lancet370, 1781–1790 (2007).
   PubMed Web of Science ®Google Scholar
• Khush KK, Waters DD, Bittner V et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation115, 576–583 (2007).
   PubMed Web of Science ®Google Scholar
• Raina A, Pickering T, Shimbo D. Statin use in heart failure: a cause for concern? Am. Heart. J.152, 39–49 (2006).
   PubMed Web of Science ®Google Scholar
• Escobar C, Echarri R, Barrios V. Relative safety profiles of high dose statin regimens. Vasc. Health Risk Manag.4, 525–533 (2008).
   PubMedGoogle Scholar
• Horwich TB, Hamilton MA, Maclellan WR et al. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J. Card. Fail.8, 216–224 (2002).
   PubMed Web of Science ®Google Scholar
• Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? J. Am. Coll. Cardiol.8, 216–224 (2002).
   Google Scholar
• Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med.357, 2248–2261 (2007).
   PubMed Web of Science ®Google Scholar
• Tavazzi L, Maggioni AP, Marchioli R et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet372, 1231–1239 (2008).
   PubMed Web of Science ®Google Scholar
• Pitt B, Loscalzo J, Ycas J et al. Lipid levels after acute coronary syndromes. J. Am. Coll. Cardiol.51, 1440–1445 (2008).
   PubMed Web of Science ®Google Scholar
• Lablanche JM, Danchin N, Farnier M et al. Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: the CENTAURUS trial design. Arch. Cardiovasc. Dis.101, 399–406 (2008).
   PubMed Web of Science ®Google Scholar
• Di Sciascio G, Patti G, Pasceri V et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial. J. Am. Coll. Cardiol.54, 558–565 (2009).
   PubMed Web of Science ®Google Scholar
• Fellström BC, Jardine AG, Schmieder RE et al. AURORA study group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med.360, 1395–1407 (2009).
   PubMed Web of Science ®Google Scholar
• Wanner C, Krane V, März W et al. Atorvastatin in patients with Type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med.353, 238–248 (2005).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Hunninghake DB, Stein EA et al. Safety of rosuvastatin. Am. J. Cardiol.94, 882–888 (2004).
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Milionis HJ, Saougos VG et al. Dose-dependent effect of rosuvastatin treatment on urinary protein excretion. J. Cardiovasc. Pharmacol. Ther.12, 292–297 (2007).
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Milionis HJ, Gazi I et al. Rosuvastatin increases α-1 microglobulin urinary excretion in patients with primary dyslipidemia. J. Clin. Pharmacol.46, 1337–1343 (2006).
   PubMed Web of Science ®Google Scholar
• Vidt DG, Cressman MD, Harris S et al. Rosuvastatin-induced arrest in progression of renal disease. Cardiology102, 52–60 (2004).
   PubMed Web of Science ®Google Scholar
• Schuster H. The GALAXY program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev. Cardiovasc. Ther.5, 177–193 (2007).
   PubMedGoogle Scholar